PKG Health is delivering precision medicine through actionable intelligence to assist in the detection and treatment of neurological conditions. The company’s platform leverages an expansive body of clinical evidence and pairs PKG’s wearable sensor with machine learning algorithms to yield data-driven insights. On the back of significant business advancements, PKG Health is pleased to announce important leadership changes.
The new appointments bring the capabilities and connections needed to enable PKG Health to build on opportunities created by the progress achieved 2024 and set the stage for the company’s continued growth and innovation in Parkinson’s disease management.
Successful launch of the Partnership Program with ActiGraph and Empatica
The partnerships with two of the leading providers of wearable digital health technology have strengthened our ability to deliver PKG Health’s most clinically validated algorithms to life science companies. These partnerships highlight the company’s dedication to driving research & development forward through cutting-edge technologies and monitoring tools.
PKG Health’s inclusion in the NHS commissioning policy in the United Kingdom
The PKG system is currently available in 45 hospitals across the United Kingdom. Its inclusion in the NHS commissioning policy will expand patient access and highlights its
potential to transform Parkinson’s care.
Expansion into the Middle East and Europe
Capitalising on growing demand for advanced healthcare solutions, further establishing its global footprint and commitment to enabling cutting-edge care worldwide, PKG Health expanded into the Middle East and deepened its presence in Europe by signing agreements with three additional home care providers in France.
Thomas Ulmer, previously Chief Operating and Financial Officer, has been appointed as Interim Chief Executive Officer to steer PKG Health’s next phase of growth with Zach Henderson leaving PKG Health as Chief Executive Officer.
Leighton Read, Chairman of the Board, “We are excited to appoint Thomas Ulmer as our Interim CEO. Thomas has been a key part of our leadership team, bringing a wealth of experience in general management and finance. His deep knowledge of the business, coupled with his proven track record in scaling up businesses, makes him the ideal person to lead PKG Health through this important phase of growth. I would like to extend our thanks to Zach Henderson for his dedication and leadership during his tenure as CEO.”
In addition to the leadership transition, PKG Health is also pleased to announce the following appointments to support the company’s next stage of strategic growth:
Dan Bennett has been promoted to Chief Business Officer
Dan will assume full responsibility for managing our relationships with life science companies and licensing partners, a key function as we expand our commercial footprint.
PKG Health is already working with leading wearable digital health technology companies in the industry. Under Dan's leadership, we will further accelerate our contribution to R&D companies around the world who are developing innovative therapies to treat Parkinson’s disease.
Neil Stevens will be promoted to Chief Commercial Officer (EMEA)
In this expanded role, Neil will lead the largest regional segment of our clinical care business, overseeing operations in Europe, the Middle East, and Australia. Neil has successfully grown our business in Europe and played a pivotal role in expanding availability of the PKG to patients in the Middle East, one of the fastest-growing regions in healthcare. His leadership will be crucial as we continue to strengthen our position in these dynamic markets.
Mandy Hagley has been promoted to Finance Director.
Mandy has been a cornerstone of our finance team, and her new role will enable her to take on greater responsibilities while continuing to provide strategic financial leadership.
These promotions recognise the exceptional contributions of our leadership team and are designed to position PKG Health for long-term success.
About PKG Health
PKG Health is a global leader in precision medicine, dedicated to transforming Parkinson’s disease management through cutting-edge technology and AI-powered solutions. Its technology has been used as endpoints in clinical trials by most of the companies studying new therapies for Parkinson’s disease. The company’s flagship clinical offering, the PKG system, combines advanced wearable devices with data-driven insights to empower clinicians and improve patient outcomes. By integrating innovative tools with validated clinical practices, PKG Health is shaping the future of neurology care and redefining the standard for personalised healthcare.
With a strong presence in Europe, the Middle East, and other key markets, PKG Health continues to expand its global footprint, forging partnerships with leading healthcare
providers and technology companies. Recognised for its inclusion in the NICE guidelines and the NHS commissioning policy in the United Kingdom, PKG Health’s solutions are trusted worldwide to deliver state-of-the-art care.